INFI News and Press, Infinity Pharmaceuticals Inc. From 08/10/22

Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals ( NASDAQ: INFI ) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced data from a two-year analysis of an ongoing study and reported Q2 results. Cambridge, Mass.-based INFI is developin...

Start Time: 16:30 End Time: 16:58 Infinity Pharmaceuticals, Inc. (INFI) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Sen...

– Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 – – MARIO-3 triple negative breast cancer (TNBC) data update on track by year end – – Fu...

Infinity Pharmaceuticals press release ( NASDAQ: INFI ): Q2 GAAP EPS of -$0.13. Revenue of $0.69M (+35.3% Y/Y). As of June 30, 2022, we had cash, cash equivalents and available-for-sale securities of $56.6M. "We believe that our existing cash, cash equivalents and ...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9 th , 2022, at 4:30 pm ET to report its fin...

The following slide deck was published by Infinity Pharmaceuticals, Inc. in conjunction with this event. For further details see: Infinity Pharmaceuticals (INFI) Investor Presentation (Slideshow)

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-o...

Infinity Pharmaceuticals, Inc. (INFI) Q1 2022 Earnings Conference Call May 03, 2022, 04:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and CEO Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Anu...

Infinity Pharmaceuticals press release (NASDAQ:INFI): Q1 GAAP EPS of -$0.14 in-line. Revenue of $0.65M (+38.3% Y/Y) beats by $0.39M. 2022 Guidance: Net Loss: Infinity expects net loss for 2022 to range from $45 million to $55 million. Cash and Investments: Infinity expects to end 2022 wi...